There's a specific silence that happens when someone mentions the CEO is still the scientist who built the product.
Not hostile. Not spoken. Just a pause where everyone in the room recalibrates their expectations for the next twelve months.
I've been placed inside enough of these conversations from the hiring side to know what that silence means. It doesn't mean the founder is incompetent. It means the company has arrived at a stage the founder wasn't designed for, and nobody's said it yet.
Here's the distinction that most commentary on this topic misses entirely.
The scientific founder is exactly the right CEO until the job changes. And the job changes at a specific moment: when the work shifts from proving the science to selling the product. Those are not variations of the same role. They require different instincts, different networks, different tolerances for the kind of ambiguity that comes from a hospital procurement cycle rather than a clinical trial protocol.
I spoke to a CHRO recently at a pre-commercial orthopaedic company. Brilliant device, genuine clinical innovation, clinical trial moving faster than anything I'd seen at that stage. She asked me about a Quality Manager hire. I didn't ask about the job spec. I asked: which company is this person currently working for right now, and where are they based?
She sat back and said there weren't any. That was the whole problem, stated in one sentence. Not a competence problem. A geography problem with a dual regulatory constraint attached. The right person existed. She was working for Smith & Nephew in London and happened to be from Worcester. They got lucky.
Most companies don't get lucky. They write a job spec that describes the person they want and then wonder why nobody suitable applies.
The CEO transition works the same way. The question isn't whether the founder can learn commercial skills. Some do. Frederic Moll founded Intuitive Surgical as a physician-CEO and built it into a company worth hundreds of billions. But Moll is a specific kind of person: clinician, entrepreneur, someone who actively built business capability alongside clinical insight. He's the exception that gets cited precisely because he's the exception.
The pattern that actually repeats across successful medical device exits looks like this: scientist or clinician builds the IP, drives early clinical validation, establishes credibility with KOLs and early investors. Around Series B or post-clearance, a commercial operator comes in as CEO with genuine medical device scar tissue: hospital sales experience, reimbursement strategy, prior exits. The founder moves to CMO or CSO. The company gets sold.
HistoSonics. Farapulse. OrganOx. The structure varies but the logic doesn't. Clinical insight launches the company. Commercial experience scales it.
The founder who makes this transition proactively — who identifies the moment before the board forces the conversation — is the one who keeps equity, keeps influence, and gets to the exit they spent a decade building towards.
The one who doesn't tends to run out of cash eighteen months after clearance. Not because the science failed. Because selling into a US hospital system is a different job from running a clinical trial, and nobody said so clearly enough, early enough.
That's the conversation the board isn't having. And it's usually the most important one on the agenda.